Lastly, our study identified a combined therapeutic strategy that the combination of USP8 inhibitor and PD-1/PD-L1 blockade could significantly reduce tumor growth and increase overall survival rate in different mouse tumor models (Fig. 6). Here, CD274 is linked to neoplasm.